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Abstract
Background: Cancer stem cell (CSC) hypothesis has not been well demonstrated by the lack of
the most convincing evidence concerning a single cell capable of giving rise to a tumor. The scarcity
in quantity and improper approaches for isolation and purification of CSCs have become the major
obstacles for great development in CSCs. Here we adopted suspension culture combined with
anticancer regimens as a strategy for screening breast cancer stem cells (BrCSCs). BrCSCs could
survive and be highly enriched in non-adherent suspension culture while chemotherapeutic agents
could destroy most rapidly dividing cancer cells and spare relatively quiescent BrCSCs.
Methods:  TM40D murine breast cancer cells were cultured in serum-free medium. The
expression of CD44+CD24- was measured by flow cytometry. Cells of passage 10 were treated in
combination with anticancer agents pacilitaxel and epirubicin at different peak plasma
concentrations for 24 hours, and then maintained under suspension culture. The rate of apoptosis
was examined by flow cytometry with Annexin-V fluorescein isothiocyanate (FITC)/propidium
iodide (PI) double staining method. Selected cells in different amounts were injected
subcutaneously into BALB/C mice to observe tumor formation.
Results: Cells of passage 10 in suspension culture had the highest percentage of CD44+CD24-
(about 77 percent). A single tumor cell in 0.35 PPC could generate tumors in 3 of 20 BALB/C mice.
Conclusion: Suspension culture combined with anticancer regimens provides an effective means
of isolating, culturing and purifying BrCSCs.
Background
In recent years there has been an increasing focus on the
cancer stem cell (CSC) theory. More and more CSCs in
solid tumors have been prospectively identified based on
expression of cell surface markers [1-5] or Hoechst 33342
dye efflux [6-9]. According to CSC hypothesis, a CSC is a
cancer-initiating cell that possesses the ability to recreate a
new tumor when transplanted into a suitable microenvi-
ronment. However, to date, there have been no studies
that convincingly put this proposition into practice. CSCs
identified from several solid tumors are only a small sub-
population of tumorigenic cells that most probably repre-
sents a heterogeneous mixture of CSCs and their
differentiated progeny. More primitive, undifferentiated
CSCs (also called true CSCs) remain hidden among them.
Since a single stem cell has been demonstrated to have the
ability to reconstitute an entirely functional organ in a
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mouse model [10-12], a single CSC with stem-like prop-
erties should also generate a tumor when injected into a
congenetic animal model. It is still unclear whether true
CSCs have unique cell surface antigens. To address this
basic issue in CSC hypothesis, we explored the possibility
of exploiting the feature of drug resistance in cancer cells
for screening CSCs on the basis of serum-free suspension
culture for isolation and in vitro propagation of tumori-
genic cancer cells. By applying suspension culture com-
bined with anticancer regimens, we obtained single breast
cancer stem cell (BrCSC), which was able to generate new
tumor when injected into congenetic mice.
Methods
In vitro propagation of BrCSCs in serum-free culture 
medium
TM40D murine breast cancer cells were kindly provided
by M. Zhang (Baylor College of Medicine, Houston,
Texas) and maintained in our laboratory. Cells were cul-
tured in serum-free DMEM/F12 (DrGenes, Shandong,
China) containing 20 ng/ml epidermal growth factor
(EGF; PeproTech Asia, Rehovot, Israel), 20 ng/ml basic
fibroblast growth factor (bFGF; R&D Systems, Minneapo-
lis, MN), 0.4% bovine serum albumin (DrGenes) and 2%
B27 (Invitrogen, Carlsbad, CA) at a density of 1000 cells/
ml. Cells were grown in T-75 culture flasks at 37°C in a
humidified atmosphere containing 5% CO2. Tumor-
spheres were passaged by mechanical dissociation to sin-
gle cells through the needle (gauge 21) of a 5 ml syringe
every 3 days and reseeded in the medium described above
at 1000 cells/ml.
Flow cytometric analysis and apoptosis measurement
To identify CD44+/CD24- cells in TM40D cell line, we
measured expression of CD44+CD24- at passages 2–16 by
using a fluorescence-activated cell sorting (FACS)-Vantage
SE instrument (Becton Dickinson, Franklin Lakes, NJ).
The antibodies used were anti-CD24-phycoerythrin (PE),
anti-CD44-PE-cyainn 5 (CY5), and their corresponding
isotype controls (BioLegend, San Diego, CA). Cells were
harvested and gently disaggregated to a single cell suspen-
sion. Staining was made according to the manufacturer's
protocol. The rate of apoptosis induced by anticancer reg-
imens was analyzed by flow cytometry using an annexin
V-FITC/PI kit (BD Biosciences, San Diego, CA) following
the manufacturer's instructions.
Anticancer regimens screening assay
Cells at passage 10 were plated at 1 × 105/ml into 24-well
plates (100 μl per well) under serum-free condition for 3
days until formation of tumorspheres consisting of hun-
dreds of cells. Then a combination with pacilitaxel (Taiji,
Sichuan, China) and epirubicin (Pfizer, Wuxi, China),
was administered at several different peak plasma concen-
trations (PPC; 1, 0.5, 0.35, 0,3, 0.25, 0.1). Each concentra-
tion was repeated thrice. The PPC of pacilitaxel and
epirubicin are 2.2 μg/ml and 0.78 μg/ml, respectively.
After incubation for 24 hours, the cells were centrifuged,
mechanically dissociated into single cells and recultured
for 7 days in fresh serum-free medium.
Tumor xenograft experiment
As described previously by Al-Hajj et al [1], four-week-old
female BALB/C mice (Shanghai Experimental Animal
Center, Chinese Academy of Sciences, Shanghai, China)
were treated with VP-16 (Double-crane, Beijing, China)
by an i.p. injection (30 mg/kg). Five days later, tumor cells
injections were done. Cells treated with 0.35 PPC of
chemotherapeutic drugs were counted in DMEM/F2 with
0.04% trypan blue (Shenggong, Shanghai, China) and
10% fetal calf serum (Sijiqing, Hangzhou, China), and
resuspended in DMEM/F2 and Matrigel (BD Biosciences)
mixture (1:1 volume). The cells were then injected s.c. in
200 μl volumes into the abdominal wall of the mice. Cell
viability was determined by trypan blue exclusion before
transplantation. The number of injected cells was
obtained with limited dilution method. After cell injec-
tion, mice received an estradiol (Tongyong, Shanghai,
China) supplementation (0.4 mg/kg s.c.) every 10 days
for 40 days and were inspected for tumor appearance by
observation and palpation as described by Ponti et al.
[19]. When the xenograft tumors grew to about 1 cm in
diameter, the mice were sacrificed by cervical dislocation
and each tumor was confirmed by routine H&E staining
for paraffin sections. Eight months later, the others that
failed to give rise to palpable nodules at the injection site
were also sacrificed and soft tissues around the injection
site were examined by H&E staining. Experimental proto-
cols were performed according to the guidelines of the
Nanjing Medical University Animal Committee.
Expression of CD44 and CD24 in xenograft tumors by 
immunohistochemical analysis
Following the diagnosis of breast cancer by H&E staining,
immunohistochemical procedures were made on 4-μm
tissue sections with monoclonal antibodies for CD44 and
CD24 (both from Boster, Wuhan, China). Immunodetec-
tion was performed using a standard SABC method. Sec-
tions were counterstained blue with hematoxylin for the
nuclei.
Results
Enrichment of the subpopulation of putative BrCSCs in 
TM40D cells under suspension conditions
TM40D murine breast cancer cells could be directly
adapted from serum-containing medium to serum-free
medium. Primary tumorspheres were initially observed at
the fifth day of serum-free culture. Large spherical aggre-
gates consisting of hundreds of cells, varying from 60 to
200  μm in diameter, formed after 7 days of cultureBMC Cancer 2008, 8:135 http://www.biomedcentral.com/1471-2407/8/135
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(Fig 1A). Tumorspheres were then disaggregated into a
single cell suspension and serially passaged at clonal den-
sity (1000 cells/ml). Secondary tumorspheres appeared
on the second day of culture. To determine the proportion
of BrCSCs in TM40D cells under suspension conditions
and obtain sufficient BrCSCs in quantity, we measured
expression of CD44+CD24- during serial passages. The
CD44+CD24-  subpopulation in TM40D cell line
accounted for 0.7 – 1.6% in serum-containing medium
(Fig. 1B). The percentage of CD44+CD24-cells had a
marked increase at passages 2 to 10 (from 3.39% up to
72.42%), and then it maintained a relatively stable pro-
portion (Fig. 2).
BrCSCs sorted by suspension culture combined with 
chemotherapeutic agents
Cells of the 10th passage under suspension culture were
incubated in combination with different concentrations
of pacilitaxel and epirubicin for 24 hours. The cells were
then washed thoroughly with HBSS to remove chemo-
therapy drugs and maintained in suspension culture by
gently agitating aggregates as single cells. By centrifugaion
to exclude dead cells and debris, fresh culture media were
replaced every 3 days. After 7 days of culture in serum-free
medium, cell apoptosis was evaluated by flow cytometry
with Annexin-V FITC/PI double staining method. As
shown in Table 1, all cells treated with 1 and 0.5 PPC of
pacilitaxel and epirubicin, i.e. TE chemotherapy protocol,
underwent apoptosis and necrosis. Cells treated with 0.25
and 0.1 PPC of TE survived, proliferated, and formed tum-
orspheres. The vast majority of cells treated with 0.35 PPC
of TE (~98%) suffered death.
CD44+CD24- expression under serum-free culture condition  during serial passages Figure 2
CD44+CD24- expression under serum-free culture 
condition during serial passages.
(A) floating tumorspheres after 6 days of suspension culture Figure 1
(A) floating tumorspheres after 6 days of suspension culture. Scale bar = 100 μm. (B) CD44+CD24- expression in 
TM40D cell line.BMC Cancer 2008, 8:135 http://www.biomedcentral.com/1471-2407/8/135
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Self-renewal and differentiation of BrCSCs in vitro
As BrCSCs have been identified as CD44+CD24- pheno-
types, we measured the expression of cells treated with
0.35 PPC of TE one week after chemotherapy. During this
period, no tumorspheres and cell proliferation were
observed under the microscope. The vast majority of cells
(>99.8%) were positively for CD44 and negatively for
CD24 (Fig. 3A). Then these cells were isolated and plated
in 96-well culture dishes at a density of 1 cell per well
under serum-free media. After another week, clusters of
cells were found in more than 90% of the wells. The tum-
orspheres were collected and dissociated as described
above, and the expression of CD44 and CD24 were eval-
uated again using flow cytometry. About 87% of cells
stained CD44+CD24- (Fig. 3B).
Tumor reconstitution by a single breast cancer cell
To test tumorigenic ability of the sorted cells, cells which
survived 0.35 PPC of chemotherapeutic agents were
injected into the abdominal wall of BALB/C mice, and
CD44+CD24+ cells and CD44+CD24- cells from the pas-
sage 10 under suspension culture were used as the control
group. One month after injection, tumors could be
observed at the injection sites of 1000 and 100 cells
treated with 0.35 PPC of TE in all mice with normal or
suppressed immune function. 1000 and 100
CD44+CD24- cells gave rise to tumors in most cases. By
contrast, 1000 or 100 CD44+CD24+cells failed to form
tumors (Table 2). After about 10 weeks, a single cell of
0.35 PPC of TE group reconstituted an entire tumor in 3
of 20 mice, one with normal immune function, the other
two with suppressed immune function (Fig. 4A). Com-
pared with previous tumor sections from TM40D cells,
tumors formed by a single sorted cell displayed the same
histological appearance by hematoxylin and eosin stain-
ing paraffin sections (Fig. 4B and 4C). The expression of
CD44 and CD24 could be found in the sections from the
xenograft tumors driven by a single sorted cell, and had
no significant differences compared with sections from
TM40D cells (Fig. 5). Eight months after tumor inocula-
tion, normal mouse tissue was observed at the injection
sites that failed to give rise to form palpable nodules by
histology.
Discussion
Since BrCSCs have been identified as CD44+CD24- sub-
population from breast cancer patient samples [1], much
progress in research on this field has been achieved. How-
ever, the isolation and purification of BrCSCs is still hin-
dered by their scarcity in quantity and continuous
differentiation. To the development of targeted therapy
against breast cancer, the key is to solve the problem from
the identification of true BrCSCs. At present, identifica-
tion of CSCs is mainly based on cell surface antigens
sorted by fluorescence-activated cell sorting or magnetic
immunosorting. As the exact molecular signature of CSCs
is not known, it seems somewhat blind and impractical in
order to find CSCs by screening large numbers of known
markers. Hoechst 33342 dye efflux, another sorting
approach in using functional properties of CSCs, are
Table 2: Engraftment of murine breast cancer cells into BALB/C 
mice
Tumors/injections
1000 100 1
Mice with normal immune function
Cells treated with 0.35 PPC of TE 7/7 7/7 1/10
CD44+CD24+ cells 0/7 0/7 -
CD44+CD24- cells 7/7 5/7 0/7
Mice with suppressed immune function
Cells treated with 0.35 PPC of TE 7/7 7/7 2/10
CD44+CD24+ cells 0/7 0/7 -
CD44+CD24- cells 7/7 7/7 0/7
Table 1: Apoptosis and necrosis induced by combination with pacilitaxel and epirubicin
Percentage of FACS events PPC of pacilitaxel and epirubicin
1 0.5 0.35 0.3 0.25 0.1
Apoptosis rate 100 100 98.28 ± 1.43 81.23 ± 3.56 - -
NOTE: not detection in 0.25 and 0.1 PPC of PE groups due to cell proliferation and formation of tumorspheres.
CD44+CD24- expression in cells treated with 0.35PPC of PE Figure 3
CD44+CD24- expression in cells treated with 
0.35PPC of PE. (A) one week after chemotherapy. (B) two 
weeks after chemotherapy.BMC Cancer 2008, 8:135 http://www.biomedcentral.com/1471-2407/8/135
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being utilized to isolate side population cells enriched in
CSCs. However, cytotoxicity of Hoechst-33342 may
restrict its further applications [13-15]. The above two
methods both use flow cytometry, and cell sorting may
cause the trauma of stained cells.
The CSC theory holds that CSCs reside in a largely quies-
cent state with regard to cell-cycle activity [16,17] and
express high levels of ATP-binding cassette (ABC) trans-
porters such as the multidrug resistance gene [18], so that
they can be more resistant to chemotherapeutics than
tumour cells with limited proliferative potential. Further-
more, it has been demonstrated that BrCSCs can be prop-
agated and passaged in vitro under serum-free suspension
culture and sustain the undifferentiated state [19]. Based
on the above theory and research results, we propose a
novel strategy-suspension culture combined with antican-
cer regimens – to screen BrCSCs. At first, we followed the
approach of Ponti et al. [19] to expand and enrich tumor-
igenic breast cancer cells under suspension culture condi-
tions. Cytotoxic regimens were then used to eradicate
rapidly dividing tumor cells but spare BrCSCs. Finally,
tumor xenograft experiments were performed to evaluate
tumorigenicity of the sorted cells. Recently, Yu et al. [20]
have successfully taken advantage of mammospheres in
suspension culture and chemotherapy to enrich for self-
renewing breast cancer cells, which further confirms our
viewpoint.
Tumorspheres could sustain long-term suspension culture
and serial passage in vitro. In our laboratory, they have
been through 110 successive passages. During the period
of serum-free culture, we observed that cells were not able
to proliferate in serum-free medium without EGF and/or
bFGF. Tumorspheres only formed in the presence of EGF
and/or bFGF. Similar results have also been in culture of
mammospheres reported by Dontu et al.[21]. We specu-
late it is EGF and/or bFGF that induce cell proliferation
under suspension culture conditions. As described by
Ponti et al. [19] and Yu et al.[20], tumorspheres were
undifferentiated cells because they failed to express
mature markers associated to myoepithelial cells (cytoker-
atin 14 and alpha-smooth muscle actin) and luminal/
ductal cells (cytokeratin 14 and MUC-1). However, it is
the relative degree of undifferentiation. In this experiment
we found that the sorted CD44+CD24- subset could gener-
ate CD44-CD24-, CD44-CD24+, and CD44+CD24+ sub-
population besides CD44+CD24- phenotype in serum-
free culture (data not shown). Even if under suspension
culture, tumorsphere cells propagate always followed by
differentiation. Before chemotherapy, more than 70% of
cells in serum-free media possessed CD44+CD24- pheno-
type. One week after chemotherapy, almost all cells
expressed CD44+CD24-.(Note early flow cytometry analy-
sis after anticancer application may affect test results as a
large number of necrotic cells and debris). The findings
showed that chemotherapy drugs killed non-
CD44+CD24- cells and only retained a very small number
of CD44+CD24- cells in 0.35 PPC of TE (less than 2%).
After about 2 weeks of quiescence and recovery, a single
surviving CD44+CD24-cell would propagate as tumor-
spheres and differentiate into a heterogenous population.
The expression of CD44 and CD24 of histological sections  by immunochemistry analysis Figure 5
The expression of CD44 and CD24 of histological 
sections by immunochemistry analysis. (A, B) CD44 
and CD24 staining from the xenograft tumors driven by a 
single sorted cell, respectively. (C, D) CD44 and CD24 stain-
ing from the xenograft tumors driven by unsorted TM40D 
cells, respectively. (both 20 objective).
(A) a visible tumor driven by a single cell in a mouse with  normal immune function Figure 4
(A) a visible tumor driven by a single cell in a mouse 
with normal immune function. (B) a pathological section 
of tumor tissues from 106 TM40D cells transplantation. (C) a 
pathological section of tumor tissues from a single breast 
cancer cell transplantation. (both 20 objective).BMC Cancer 2008, 8:135 http://www.biomedcentral.com/1471-2407/8/135
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These cells exhibted the ability of self-renewal and
multipotent differentiation in virto suspension culture.
In order to obtain a true, single BrCSC, we have proposed
in vitro suspension culture growth pattern to describe the
properties of BrCSCs from suspension culture in vitro
[22]. Tumorspheres consist of BrCSCs and transit amplify-
ing cells/progenitors, which may be compared to the
structure of an atomic model. A few BrCSCs locate inside
the core of tumorsphere (viewed as an atomic nucleus)
and a large amount of relatively differentiated progenies
surround the outer layer (viewed as electrons). BrCSCs
simultaneously perpetuate themselves through symmetric
division and generate differentiated progeny through
asymmetric division [23,24]. Self-renewal of BrCSCs is
limit and tumorpsphere formation is mainly due to
expansion of their progeny (rapidly dividing cells, also
termed transit amplifying cells). A possible mechanism
may involve that BrCSCs have a relatively slow turnover
rate to ensure uniform genetic background and rapid
expansion of transit amplifying cells prevent neighboring
BrCSCs proliferating via unknown regulation. As gentle
mechanical aspiration can disperse tumorspheres, surface
tension may play a key role in tumorpsphere formation
rather than cell-cell interactions. From this hypothesis
model, we can speculate that a certain size tumorsphere
should contain the largest proportion of BrCSCs. To
obtain a large number of BrCSCs, it is necessary to disso-
ciate the optimal size of tumorspheres into single cells. In
this way, single BrCSC is exposed again and another self-
renewal process will continue. By measuring
CD44+CD24-  expression of tumorsphere cells during
serial passages, we found that it had the highest propor-
tion of CD44+CD24- cells at passage 10. Cells of passage
10 were therefore the most desirable research subjects. As
shown in Fig. 2, the proportion of CD44+CD24-subpopu-
lation exhibited a rough S-shaped curve. This suggests that
CD44+CD24- cells has achieved stable proportion after
some passages of suspension culture and BrCSCs may
reside in a relatively slow proliferation period or a quies-
cent state, whereas their differentiated progeny may sus-
tain expansion in number. During this time, most BrCSCs
can survive the attack of chemotherapy drugs. Pacilitaxel
and epirubicin, which mainly target rapidly dividing
tumor cells, are widely used against breast cancer as a
combined chemotherapy protocol. It is a critical issue to
determine the optimal concentrations of TE. The criteria is
required to comply with the requirements of eradicating
the vast majority of dividing cells and retaining the mini-
mum number of dormant cells. Less than 2% of the cells
treated with 0.35 PPC of TE survived the double sorting of
suspension culture and anticancer regimens. In theory,
these sorted cells were much closer to the source of prim-
itive BrCSCs. In contrast, the other concertrations of
chemotherapy drugs would kill all tumor cells or would
not stop cell proliferation in our study.
Tumorigenicity test are currently been regarded as the
gold standard for proving the existence of CSCs. The key
to a successful transplantation is to keep cell viability.
Before single-cell inoculation, each cell was evaluated by
trypan blue staining to exclude dead cells. At the same
time matrigel and estrogen were both applied. Matrigel
can provide a more favourable microenvironment niche
for cell colonization and growth. Exogenous estrogen sup-
plementation can promote tumor formation. In this
study, in order to avoid transplantation rejection in the
use of human breast cancer cells and immunocompro-
mised mice, we adopted the established breast cancer cell
line TM40D from BALB/C mice. Although congenic trans-
plantations were used, we applied VP-16 before transplan-
tation in order to reduce immune and inflammation
response and guarantee the viability of cells after inocula-
tion under the consideration of transplantation of a small
number of tumor cells at initial design stage, especially for
a single-cell transplantation. In fact, the transplantation
results showed there were no distinct difference between
the non-immunosupressed and immunosuppressed
group in this study. It suggests that immune function may
have no apparent effect on syngeneic tumor transplanta-
tion of inbred mice. The immunochemical analysis of the
resulting tumors driven by a single sorted cell showed a
heterogenous tumor in vivo, with the similar features
compared with primary tumors from TM40D cells. Taken
in vitro and in vivo experimental studies together, we con-
clude that the sorted cells are true BrCSCs.
As a functional sorting method, suspension culture com-
bined with anticancer regimens provides us a novel
approach to enrich and purify CSCs. At the pre-experi-
ment, we adopted CD29 and CD24 as the presumed
markers of BrCSCs according to CD29hiCD24+  from
mouse mammary epithelium stem cell identified by
Shackleton et al. [12]. We found no tumors were formed
by injecting 104 CD29hiCD24+ cells or CD29hiCD24- into
BALB/C mice. The result reminded us that there may be
unknown or no specific cell surface antigens highly
expressed in BrCSCs. So we bagen to enrich tumorgenic
breast cancer cells by serum-free suspension culture and
purify BrCSCs by chemotherapy drugs. The results showed
BrCSCs in mice derived from CD44+CD24- subpopula-
tion and had the same markers of puative BrCSCs in
human. By applying this sorting stragegy, we could
expand and purify CSCs under the condition of unknown
putative markers in vitro. Similarly, we could also obtain
CSCs much closer to the source under the condition of
known putative markers. It could not be made only by
flow sorting of the original cultures.BMC Cancer 2008, 8:135 http://www.biomedcentral.com/1471-2407/8/135
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Conclusion
In this study, we identified BrCSCs by suspension culture
combined with anticancer regimens and confirmed that a
single BrCSC can form breast cancer in mice. We showed
for the first time, to our knowledge, that a single tumor
cell can repopulate a new tumor in mice with normal
immune function. The sorting method of suspension cul-
ture combined with anticancer regimens for BrCSCs may
be applied to identify other CSCs in solid tumors.
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